200 results on '"Sharpe, Sally A."'
Search Results
2. Immune cell population dynamics following neonatal BCG vaccination and aerosol BCG revaccination in rhesus macaques
3. Intravenous BCG vaccination in non-human primates induces superior serum antibody titers with enhanced avidity and opsonizing capacity compared to the intradermal route
4. A Multi-Task Self-Normalizing 3D-CNN to Infer Tuberculosis Radiological Manifestations
5. Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates
6. Mtb -Specific HLA-E-Restricted T Cells Are Induced during Mtb Infection but Not after BCG Administration in Non-Human Primates and Humans.
7. High-dose Mycobacterium tuberculosis aerosol challenge cannot overcome BCG-induced protection in Chinese origin cynomolgus macaques; implications of natural resistance for vaccine evaluation
8. Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19
9. ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
10. A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates
11. Differences in host immune populations between rhesus macaques and cynomolgus macaque subspecies in relation to susceptibility to Mycobacterium tuberculosis infection
12. MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies
13. Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines
14. CD1b-restricted GEM T cell responses are modulated by Mycobacterium tuberculosis mycolic acid meromycolate chains
15. IV BCG Vaccination and Aerosol BCG Revaccination Induce Mycobacteria-Responsive γδ T Cells Associated with Protective Efficacy against M. tb Challenge
16. Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates
17. Quantitative and qualitative iNKT repertoire associations with disease susceptibility and outcome in macaque tuberculosis infection
18. Immune cell population dynamics following neonatal BCG vaccination and aerosol BCG revaccination in rhesus macaques
19. T cell responses to simian immunodeficiency virus
20. Route of delivery to the airway influences the distribution of pulmonary disease but not the outcome of Mycobacterium tuberculosis infection in rhesus macaques
21. Ultra low dose aerosol challenge with Mycobacterium tuberculosis leads to divergent outcomes in rhesus and cynomolgus macaques
22. Author Correction: The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays
23. Differences in monocyte: lymphocyte ratio and Tuberculosis disease progression in genetically distinct populations of macaques
24. Surveillance of daughter micronodule formation is a key factor for vaccine evaluation using experimental infection models of tuberculosis in Macaques
25. Surveillance of Daughter Micronodule Formation Is a Key Factor for Vaccine Evaluation Using Experimental Infection Models of Tuberculosis in Macaques
26. Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of Mycobacterium tuberculosis Infection
27. Surveillance of Daughter Micronodule Formation is A Key Factor for Vaccine Evaluation Using Experimental Infection Models of Tuberculosis in Macaques
28. Unsupervised CT Lung Image Segmentation of a Mycobacterium Tuberculosis Infection Model
29. Identification of HLA-E Binding Mycobacterium tuberculosis–Derived Epitopes through Improved Prediction Models
30. Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M. tb)
31. Influence of Aerosol Delivered BCG Vaccination on Immunological and Disease Parameters Following SARS-CoV-2 Challenge in Rhesus Macaques
32. Dynamics of Macrophage, T and B Cell Infiltration Within Pulmonary Granulomas Induced by Mycobacterium tuberculosis in Two Non-Human Primate Models of Aerosol Infection
33. Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination
34. A Model for Evaluating Vaccine Strategies against TB Reactivation in Asian Origin Cynomolgus Macaques: A Pilot Study Using BCG Vaccination
35. Characterization of the Infant Immune System and the Influence and Immunogenicity of BCG Vaccination in Infant and Adult Rhesus Macaques
36. The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells
37. Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques
38. Cheap and Commonplace: Making the Case for BCG and γδ T Cells in COVID-19
39. TB and SIV Coinfection; a Model for Evaluating Vaccine Strategies against TB Reactivation in Asian Origin Cynomolgus Macaques: A Pilot Study Using BCG Vaccination
40. One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model
41. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel
42. High dose aerosol challenge with Mycobacterium tuberculosis fails to overcome BCG vaccination-induced protection in cynomolgus macaques of Chinese origin: implications of natural resistance for TB vaccine evaluation.
43. One or two dose regimen of the SARS-CoV-2 synthetic DNA vaccine INO-4800 protects against respiratory tract disease burden in nonhuman primate challenge model
44. Differences in Host Immune Populations Between Rhesus Macaques and Cynomolgus Macaque Subspecies, in Relation to Susceptibility to Mycobacterium Tuberculosis Infection.
45. Induction of specific antibodies, IgG-secreting plasmablasts and memory B cells following BCG vaccination
46. ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
47. mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection
48. Immunological and pathological outcomes of SARS-CoV-2 challenge after formalin-inactivated vaccine immunisation of ferrets and rhesus macaques
49. Comparison of Rhesus and Cynomolgus macaques as an authentic model for COVID-19
50. Defining appropriate antibiotic prescribing in primary care: A modified Delphi panel approach
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.